Provided by Tiger Trade Technology Pte. Ltd.

Capricor Therapeutics

28.84
-1.1150-3.72%
Volume:627.48K
Turnover:18.20M
Market Cap:1.65B
PE:-12.76
High:30.46
Open:29.62
Low:28.37
Close:29.95
52wk High:40.37
52wk Low:4.30
Shares:57.37M
Float Shares:48.42M
Volume Ratio:0.35
T/O Rate:1.30%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.2601
EPS(LYR):-2.2601
ROE:-46.56%
ROA:-25.68%
PB:5.41
PE(LYR):-12.76

Loading ...

Capricor Shares Rise 11% After FDA Resumes Review of Co's Drug for Muscle-Wasting Condition

THOMSON REUTERS
·
Mar 10

FDA sets Aug. 22, 2026 PDUFA date for Capricor’s deramiocel BLA after lifting CRL

Reuters
·
Mar 10

Capricor Therapeutics Inc - Pdufa Target Action Date for Deramiocel Set for August 22, 2026

THOMSON REUTERS
·
Mar 10

Capricor Therapeutics Inc - Expects Eligibility for Priority Review Voucher Upon Deramiocel Approval

THOMSON REUTERS
·
Mar 10

Capricor Therapeutics Announces Establishment of New PDUFA Date for Deramiocel BLA

GlobeNewswire
·
Mar 10

What's Going On With Moderna, Capricor, Other Biotech Stocks On Monday?

Benzinga
·
Mar 10

BUZZ-U.S. STOCKS ON THE MOVE-Biotechs, Agilent, Dow

Reuters
·
Mar 09

BUZZ-Biotechs gain as FDA vaccines chief's exit seen as easing regulatory pathway

Reuters
·
Mar 09

Capricor Therapeutics to Present Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Update on March 12

GlobeNewswire
·
Mar 09

BUZZ-Uniqure jumps after FDA vaccines chief Vinay Prasad to step down

Reuters
·
Mar 07

MAHA Is Bringing Chaos to Biotech Investment Beyond Just Vaccines -- Heard on the Street -- WSJ

Dow Jones
·
Mar 03

Capricor Therapeutics to Present Late-Breaking Phase 3 HOPE-3 Deramiocel Data at MDA Clinical and Scientific Conference

Reuters
·
Feb 24

Capricor Therapeutics stellt neue Pipeline-Strategien und Fortschritte bei Duchenne-Muskeldystrophie-Therapien vor

Reuters
·
Feb 05

FDA Requests Additional HOPE-3 Data for Capricor's Deramiocel Approval Review

Reuters
·
Jan 20

Capricor Therapeutics Inc - FDA Requests Hope-3 Clinical Study Report for Bla Review

THOMSON REUTERS
·
Jan 20

Capricor Therapeutics Inc: FDA Did Not Request Any Additional Clinical Studies or New Patient Data as Part of This Request

THOMSON REUTERS
·
Jan 20

Capricor Therapeutics Inc - FDA Requests Full Hope-3 Report to Address Crl

THOMSON REUTERS
·
Jan 20

Capricor Therapeutics Inc - Expects to Submit Bla Updates in February 2026

THOMSON REUTERS
·
Jan 20

Capricor Therapeutics: HOPE-3 Success, De-Risked Regulatory Path, and Priority Review Voucher Upside Support Buy Rating

TIPRANKS
·
Jan 20

A Look At Capricor Therapeutics (CAPR) Valuation After Deramiocel Phase 3 Success And Nippon Shinyaku Deals

Simply Wall St.
·
Jan 13